Agonists of Proteinase-Activated Receptor-2 Stimulate Upregulation of Intercellular Cell Adhesion Molecule-1 in Primary Human Keratinocytes via Activation of NF-kappa B  by Buddenkotte, Jörg et al.
Agonists of Proteinase-Activated Receptor-2 Stimulate
Upregulation of Intercellular Cell Adhesion Molecule-1 in
Primary Human Keratinocytes via Activation of NF-kappa B
Jo¨rg Buddenkotte, Christopher Stroh,w Ingo H. Engels,w Corinna Moormann, Victoria M. Shpacovitch,
Stephan Seeliger, Nathalie Vergnolle,z Dietmar Vestweber,y Thomas A. Luger, Klaus Schulze-Osthoff,w
and Martin Steinhoff
Department of Dermatology and Ludwig Boltzmann Institute for Cell Biology and Immunobiology of the Skin, University of Mu¨nster, Mu¨nster, Germany;
wDepartment of Experimental Dermatology, Institute of Immunology & Cell Biology, University of Mu¨nster, Mu¨nster, Germany; zDepartment of Pharmacology &
Experimental Therapeutics, University of Calgary, Calgary, Canada; yMax-Planck Institute for Vascular Biology & Center for Molecular Biology of Inflammation
(ZMBE), University of Mu¨nster, Mu¨nster, Germany
Proteinase-activated receptor-2 (PAR2) belongs to a new G protein-coupled receptor subfamily that is activated by
various serine proteases. Recent knowledge indicates that PAR2 is involved in cutaneous inﬂammation and im-
mune response. PAR2 is highly expressed by human keratinocytes (KTC). The underlying mechanisms of PAR2-
mediated KTC function and cutaneous immune response are, however, still incomplete. Therefore, we investigated
the activation of important signaling cascades in primary human KTC after PAR2-stimulation using specific ago-
nists. Moreover, we compared PAR2-immunoreactivity in the epidermis of inﬂammatory dermatoses and normal
human skin. Electrophoretic mobility shift assays and morphological transduction studies revealed PAR2-induced
activation and translocation of nuclear factor kappa B (NF-jB) in primary human KTC with a maximum after 1 h.
Supershift analysis demonstrated acivation of the p50/p65 heterodimer complex. PAR2 agonists also induced
upregulation of intercellular adhesion molecule-1 (ICAM-1) RNA, as shown by RT-PCR. Use of NF-jB inhibitors
prevented upregulation of the cell adhesion molecule ICAM-1 in KTC indicating a direct role of NF-jB in PAR2-
mediated upregulation of ICAM-1. Fluorescence-activated cell sorter analysis conﬁrmed PAR2-induced and NF-jB-
mediated upregulation of ICAM-1 protein after 13 h. Moreover, increased expression of PAR2 was detected in KTC
of patients with atopic dermatitis suggesting a role of PAR2 in human skin inﬂammation. In conclusion, PAR2
induces upregulation of cell adhesion molecules such as ICAM-1 in primary human KTC via NF-jB activation, and is
upregulated in KTC during cutaneous inﬂammation. Thus, PAR2 may play an important regulatory role of human
KTC during inﬂammation and immune response.
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Proteinase-activated receptor-2 (PAR2) belongs to a new
subfamily of G protein-coupled receptors with seven trans-
membrane domains that are activated by various serine
proteases such as thrombin, trypsin, tryptase, cathepsin G,
neuronal, bacterial as well as house dust mite proteases. So
far, four PARs have been cloned and characterized (Dery
et al, 1998; Mcfarlane et al, 2001; Rattenholl and Steinhoff,
2003; Steinhoff et al, 2004).
It is well established that serine proteases regulate im-
portant biological effects in the skin such as inflammation,
immune response, host defense, chemotaxis, cytokine and
growth factor release, vascular function, tissue repair, and
apoptosis (Rattenholl and Steinhoff, 2003). Some of these
effects may be at least in part mediated via activation of
PAR, which thereby contribute to skin homeostasis and
disease. For example, inflammatory mediators such as
tumor necrosis factor (TNF)-a, interleukin (IL)-1a, and lip-
opolysaccharide (LPS) upregulate PAR2 in endothelial cells
(Nystedt et al, 1996), and PAR2 agonists are capable of
regulating expression and release of inflammatory media-
tors such as cytokines, prostanoids, neuropeptides, and
nitric oxide (Dery et al, 1998; Mcfarlane et al, 2001). More-
over, PAR2 agonists induce leukocyte rolling, cell adhesion,
and leukocyte extravasation in rats (Steinhoff et al, 1999;
Vergnolle, 1999; Lindner et al, 2000) and mice in vivo. Un-
fortunately, in vivo data from human tissues correlated with
in vitro data in human cells are very rare.
In the skin, PAR2 is expressed by keratinocytes (KTC),
endothelial cells, smooth muscle cells, and neurons (Santulli
et al, 1995; Derian et al, 1997; Hou et al, 1998; Schechter
et al, 1998, Steinhoff et al, 1999, 2000). In KTC, PAR2 ago-
nists inhibit growth and differentiation (Derian et al, 1997),
stimulate secretion of cytokines (Wakita et al, 1997; Hou
et al, 1998), and regulate pigmentation (Seiberg et al, 2000).
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Moreover, tryptase released from mast cells during inflam-
mation and hypersensitivity activates PAR2 in human KTC
(Steinhoff et al, 1999) resulting in activation of intracellular
Ca2þ and inositol triphosphate (IP3) hydrolysis (Santulli et al,
1995). PAR2 agonists stimulate activation of IKKa, b, and
nuclear factor kappa B (NF-kB) in a transfected KTC cell line
(Kanke et al, 2001). Thus, PAR2 may stimulate NF-kB-me-
diated inflammatory and immune responses in human skin.
The intercellular cell adhesion molecule ICAM-1 is an
important regulator of KTC function involved in cell adher-
ence, tumor progession, and tumor development (Johnson
et al, 1999; Huang et al, 2000). Furthermore, its inducible
expression is vital to the initiation of localized inflammatory
processes (Caughman et al, 1992), e.g., by recruiting T cells
to epithelial KTC (Singer et al, 1990). Therefore, ICAM-1 in-
teracts with the highest affinity to the integrin family mem-
ber lymphocyte function-associated antigen-1 (LFA-1) to
mediate adhesion. Although LFA-1 expressed on circulating
lymphocytes has low avidity to bind ICAM-1, activation of
specific G protein-coupled receptors leads to an increase of
LFA-1 avidity. Once able to firmly adhere to ICAM-1, LFA-1
is involved in attaching to blood vessels to facilitate extra-
vasation of immune cells, migration within tissues and for-
mation of the immunological synapse between T cells and
antigen-presenting cells. Interestingly, efalizumab, a hu-
manized antibody against CD11a that blocks the binding of
LFA-1 to ICAM-1 shows significant anti-inflammatory ef-
fects in human inflammatory skin diseases (Krueger, 2002).
PAR2 has been demonstrated to play a significant role
in cutaneous inflammation by a neurogenic mechanism
(Steinhoff et al, 2000). It is well known that the mast cell
proteinase tryptase is released at sites of inflammation.
Moreover, KTC (Franzke et al, 2000) and endothelial cells
(Koshikawa, 1997) release extrapancreatic trypsins that are
involved in inflammation and activation of PAR2 (Mcfarlane
et al, 2001; Cottrell et al, 2004). Therefore, one may spec-
ulate that PAR2 agonists directly affect KTC function during
inflammation and immune response, e.g., by regulating cell
adhesion molecule expression in these cells.
Although PAR2-mediated NF-kB activation was deter-
mined in transfected KTC in vitro, the precise effects of
PAR2-mediated NF-kB activation and expression of PAR2
on primary KTC during cutaneous inflammation is still un-
known. Therefore, we investigated the effects of PAR2-
induced NF-kB-mediated ICAM-1 regulation in primary
human KTC. Our aims were to (a) determine whether
PAR2 induces NF-kB activation in human primary KTC by
electrophoretic mobility shift assay (EMSA), (b) determine
the PAR2-activated NF-kB subunit complex by supershift
analysis, (c) define whether PAR2 upregulates ICAM-1 ex-
pression on human primary KTC using semiquantitative RT-
PCR and fluorescence-activated cell sorter (FACS), (d) de-
termine whether PAR2 induced ICAM-1 upregulation may be
mediated via NF-kB, and (e) verify whether PAR2 is upreg-
ulated in KTC of patients with atopic dermatitis (AD).
Results
PAR2 activates transcription factor NF-jB The transcrip-
tion factor NF-kB is a potential candidate for mediating
PAR2-induced ICAM-1 regulation in primary human KTC.
The promotor region of this cell adhesion molecule shows
binding sites for several transcription factors including NF-
kB (Hou et al, 1994; Ledebur et al, 1995). To examine the
activation of NF-kB by PAR2 agonists, we performed EMSA
studies using total cell extracts of agonist-stimulated pri-
mary human KTC. We observed a strong NF-kB activation
by trypsin (1  107, 1  109 M) with a peak after 1 h that
declined after 2 h (Fig 1A). This activation seems not only to
be time-dependent but also concentration-dependent since
1  107 M trypsin showed a stronger effect on NF-kB ac-
tivation than 1  109 M trypsin. Consistently, stimulation
with activating peptide SLIGRL-NH2 (AP) also resulted in an
upregulation of activated NF-kB within 1 h (Fig 1B). In con-
trast, reverse peptide LRGILS-NH2 (RP) failed to effect NF-
kB activation (Fig 1C), indicating that PAR2 is responsible for
activation of NF-kB in primary human KTC. Specifity was
confirmed using TNF-a as a positive control for NF-kB ac-
tivation in primary human KTC.
The NF-jB complex consists of a p65/p50 hetero-
dimer To confirm the biological functionality of the PAR2
activated NF-kB complex we investigated the protein com-
position of the DNA–protein band by supershift analysis. So
far, five mammalian NF-kB/Rel proteins are known. The AP-
activated NF-kB complex (same sample as used in Fig 1B,
lane 5) was shifted completely with an antibody directed
against p50 or with anti-p65 (Rel A), whereas antibodies di-
rected against p52, c-Rel, or RelB failed to bind to the NF-kB
complex (Fig 2). These results demonstrate that the AP-ac-
tivated NF-kB complex consists of a p65/p50 heterodimer.
Figure1
Time-course of proteinase-activated receptor-2 (PAR2)-mediated
activation of nuclear factor kappa B (NF-jB). Primary human ker-
atinocytes were stimulated for the indicated times (min) with trypsin
(107 or 109 M) (A), activating peptide (5  105 M) (B) or reverse
peptide (5  105 M) (C). Cytosolic extracts were then prepared, in-
cubated with 32P-labeled oligonucleotides containing a NF-kB binding
motif, and analyzed by electrophoretic mobility shift assay (EMSA).
PAR2 specific activation of NF-kB is confirmed by using the PAR2-
specific activating peptide and the control peptide RP (reverse peptide
LRGILS-NH2). Unstimulated (Co) and tumor necrosis factor (TNF)-a (T;
30 min, 25 ng per mL) treated cells served as controls. An arrowhead
indicates the position of the NF-kB DNA complexes. A slower () and a
faster (o) migrating nonspecific complex are indicated.
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Activation of NF-kB transcription factor upon PAR2 ago-
nist stimulation was also observed with indirect immuno-
fluorescence staining of permeabilized cells with a
monoclonal p65 antibody. PAR2-induced activation result-
ed in a nuclear translocation of cytosolic pools of NF-kB
induced by trypsin and AP (5  105 M) but not by RP
(5  105 M). This effect was also not observed in untreated
KTC (data not shown). These results were in coincidence
with our data concerning the detection of NF-kB activation
by EMSA.
PAR2 stimulates ICAM-1 mRNA expression via NF-
jB We tested our hypothesis that PAR2 is involved in the
NF-kB-mediated regulation of ICAM-1 using the semiquan-
titative RT-PCR approach. KTC were harvested 6 h after
stimulation with trypsin (107 M), AP (5  105 M), and RP
(5  105 M). To investigate the role of NF-kB, cells were
pre-treated with the NF-kB-specific inhibitor BAY11-7082 1
h before agonist stimulation. Total RNA was isolated from
the cells as described in Materials and Methods. To con-
sider the relative mRNA amount in the samples amplifica-
tion of the housekeeping gene b-actin served as an internal
control. Trypsin and AP induced a marked upregulation of
ICAM-1 as compared with the unstimulated controls where-
as the serine proteinase was more potent than the synthetic
activating peptide (Fig 3). Stimulation of primary KTC with
RP did not evoke ICAM-1 uptake (Fig 3). Use of NF-kB
inhibitor BAY11-7082 prevented upregulation of the cell
adhesion molecule expression by trypsin and AP indicating
a role of NF-kB in PAR2-mediated upregulation of ICAM-1.
Identical results were obsessed using NF-kB inhibitor
MG132 (data not shown).
PAR2 induces ICAM-1 upregulation on the cell surface
mediated by NF-jB To test the hypothesis whether PAR2
induces NF-kB-mediated upregulation of ICAM-1 also on
the protein level, we carried out cell surface ICAM-1 FACS
analysis. Therefore, cells were harvested after a 13 h incu-
bation with PAR2 stimuli and were incubated with a specific
monoclonal antibody against ICAM-1. As predicted, AP and
trypsin stimulated an increase of ICAM-1 on the cell surface
whereas RP and denaturated trypsin failed to regulate
ICAM-1 (Fig 4). 100 nM trypsin caused a 5.3-fold and 10 nM
trypsin a 2.8-fold and therefore concentration-dependent
upregulation of ICAM-1 protein as compared to the unstim-
ulated control (Fig 4A). AP induced upregulation of the cell
surface ICAM-1 by 3.3-fold as compared to RP control
(Fig 4B). Furthermore, cells treated with the NF-kB inhibitor
BAY11-7082 did not show upregulation of ICAM-1 and re-
vealed nearly similar amounts of detected protein (Fig 4A/B).
Figure 2
Proteinase-activated receptor-2 (PAR2)-activated nuclear factor
kappa B (NF-jB) complex consists of a p50/ p65 heterodimer.
Cytosolic extract of AP (activating peptide SGLIRL-NH2)-stimulated
primary human keratinocytes (same as sample taken for Fig 1B, lane 5)
was incubated with 32P-labeled oligonucleotides containing a NF-kB-
binding motif and with antibodies directed against NF-kB subunits p50
(lane 2), p52 (lane 3), p65 (lane 4), c-Rel (lane 5) and Rel B (lane 6). A
slower () and a faster (o) migrating non-specific complex are indicated.
Figure 3
PAR2 is involved in the up-regulation if ICAM-1 RNA in keratino-
cytes mediated by NF-jB, as shown by RT-PCR analysis. ICAM-1
mRNA was detected 6h after treatment of keratinocytes with PAR2
agonists alone (lanes 2,3) and disappeared after additional preincuba-
tion with the NF-kB inhibitor BAY11-7082 (lanes 6,7). 1, control; 2,
trypsin 100 nM; 3, SGLIRL-NH2 5  105 M; 4, LRGILS-NH2 5  105;
lanes 5–8 indicate same samples as lanes 1–4, but were pre-incubated
with BAY11-7082, as described in Materials and Methods.
Figure4
Fluorescence-activated cell sorter (FACS) analysis reveals pro-
teinase-activated receptor-2 (PAR2)-induced and nuclear factor
kappa B (NF-jB)-mediated upregulation of intercellular cell adhe-
sion molecule-1 (ICAM-1) protein after 13 h. (A) ICAM-1 is upreg-
ulated by trypsin in a concentration-dependent manner (circles).
Specific NF-kB inhibitor BAY11-7082 prevented trypsin-induced
ICAM-1 uptake (squares). (B) AP (activating peptide SGLIRL-NH2) al-
so stimulates a significant ICAM-1 (black bar) uptake, whereas NF-kB
inhibitor BAY11-7082 (gray bars) markedly abolishes this effect. RP
(reverse peptide LRGILS-NH2) and inactived trypsin (dt) do not stim-
ulate ICAM-1 upregulation.
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We did not observe ICAM-1 shedding by PAR2-AP by FACS
analysis (not shown). Usage of the NF-kB inhibitor BAY11-
7082 was not toxic to the cells as analyzed by a cell death
detection ELISA (data not shown).
PAR2 expression correlates with ICAM-1 expression on
human KTC Studying the effects of PAR2 agonist stimula-
tion on ICAM-1 expression in primary human KTC, we in-
vestigated whether these cells co-express PAR2 and ICAM-
1 on the cell surface by FACS analysis. The amount of
PAR2-positive cells among the whole population of human
KTC was about 16% (Fig 5). According to our data, how-
ever, almost all PAR2 expressing KTC also express ICAM-1
(Fig 5).
PAR2 is increased in lesional skin of patients with AD To
compare PAR2 immunoreactivity in skin biopsies from les-
ional skin of AD patients to controls (non-lesional AD skin,
normal human skin), immunohistochemistry was performed
as described in Materials and Methods. Fig 6A depicts the
distribution of PAR2 in normal human skin demonstrating
homogenous and predominantly membrane-associated
staining of KTC mainly in the spinous layer. Negative con-
trols did not exhibit epidermal staining for PAR2 (Fig 6B). In
lesional skin of AD patients, increase of PAR2 staining was
obtained in all layers of the epidermis as well as in the cy-
toplasm, most probably reflecting PAR2 immunoreactivity in
Golgi-pools of KTC (Fig 6C). Relatively weaker staining for
PAR2 was detected in KTC from non-lesional skin of AD
patients (Fig 6D). Thus, PAR2 immunoreactivity was en-
hanced in lesional skin of AD patients.
Discussion
Our results show that PAR2 induces activation of the p50/
p65 NF-kB complex in primary human KTC. PAR2 also
stimulates upregulation of ICAM-1 via activation of NF-kB
since inhibitors of NF-kB significantly downregulate PAR2-
induced ICAM-1 expression in these cells. Moreover, PAR2
immunoreactivity is markedly enhanced in KTC of lesional
skin from patients with AD. In conclusion, PAR2 induces
Figure5
Co-localization of proteinase-activated receptor-2 (PAR2) and
intercellular cell adhesion molecule-1 (ICAM-1) on human keratin-
ocytes (KTC). Using double-staining fluorescence-activated cell sorter
(FACS) analysis, we revealed co-localization of PAR2 (fluorescein is-
othiocyanate (FITC)-conjugated) and ICAM-1 (PE-conjugated) on hu-
man KTC. Double-labeling was observed in 15.97% of stained cells
(upper right square of presented dot-plot). Thus, almost all PAR2-ex-
pressing cells also express ICAM-1 (PAR2 positive, but ICAM-1 neg-
ative cells are localized in lower right square of presented dot-plot. The
amount of these cells is about 1%).
Figure 6
Immunohistochemical staining of skin
biopsies from patients with atopic
dermatitis (AD) and normal skin. (A)
Membrane-associated immunostaining for
proteinase-activated receptor-2 (PAR2) in
lesional skin of AD patients (  200). (B)
Negative (pre-absorption) control shows
lack of staining for PAR2 in normal human
skin (  100). (C) Immunostaining for
PAR2 in lesional skin of AD. Note the in-
tense membrane and cytoplasmic stain-
ing in all layers of human skin epithelium.
Moreover, positive staining for PAR2 in
certain inflammatory cells in the dermis
and endothelial cells (  200). (D) As com-
pared with lesional skin, homogenous but
weaker staining for PAR2 in the epidermis
and dermis of non-lesional skin in AD
(  200).
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NF-kB activation thereby upregulating cell adhesion mole-
cules such as ICAM-1 on primary human KTC. Thus, NF-kB
may mediate some of the effects of PAR2 on human KTC
under physiological and pathophysiological conditions such
as cell adhesion molecule regulation. From these data, one
may speculate that PAR2 plays an important role for the
regulation of inflammatory skin diseases such as AD or
psoriasis, frequent inflammatory skin disease characterized
by enhanced synthesis of ICAM-1 on KTC. This effect may
be crucial for the recruitment of T cells to the site of in-
flammation and immigration into the epidermis. Thus, PAR2
may directly regulate T cell recruitment via ICAM-1 during
cutaneous inflammation.
Upregulation of KTC ICAM-1 in human skin by PAR2 In
the skin, cell adhesion molecules from the Ig superfamily
such as ICAM-1 and vascular cell adhesion molecule
(VCAM)-1 mediate the adhesion and transendothelial mi-
gration through binding to b2- and b1-integrins on leuco-
cytes. In KTC, ICAM-1 appears to be crucial for cell
homeostasis and recruitment of T cell into the epidermis
(Singer et al, 1990). Pro-inflammatory mediators such as
TNF-a, IFN-g, and IL-1, and UV-B light may regulate ICAM-1
expression (Caughman et al, 1992). The role of serine pro-
teinases and PAR2 on ICAM-1 expression and regulation
has, however, not been explored as of yet.
Increasing evidence is accumulating that serine protein-
ases play an important role in physiological and pathophys-
iological processes of human skin. These effects are partly
mediated by activation of PAR (Dery et al, 1998; Mcfarlane
et al, 2001). In the skin, PAR2 is expressed by KTC, end-
othelial cells, sensory nerves (Hou et al, 1998; Steinhoff et al,
1999, 2000), and mast cells (D’Andrea et al, 2000; Nishikawa
et al, 2000). In KTC, PAR2 has been well characterized as a
negative regulator of differentiation and proliferation (Santulli
et al, 1995; Derian et al, 1997). Additionally, PAR2 agonists
such as tryptase (Schechter et al, 1998; Steinhoff et al,
1999), or endothelial-derived trypsin (Koshikawa et al, 1997),
bacterial (Lourbakos et al, 1998) or house dust mite antigens
(Sun et al, 2001) may be involved in cutaneous inflammation
via activation of PAR2, e.g., by releasing IL-8 (Hou et al,
1998), IL-1b (M. Steinhoff, unpublished observation) and
growth factors such as granulocyte macrophage-colony
stimulating factor (GM-CSF) (Wakita et al, 1997).
Our results support the idea of an important role of PAR2
for the regulation of ICAM-1 in human skin. FACS analysis
reveals a marked co-expression of PAR2 and ICAM-1 in
cultured human primary KTC (Fig 5) indicating that anatom-
ically PAR2 is capable of regulating ICAM-1 expression. By
semiquantitative RT-PCR and FACS, we demonstrate that
PAR2 upegulates ICAM-1 both at the RNA- and protein-level
in human primary KTC. These effects were observed using
various PAR2 agonists that underline the specifity of these
effects. Together, PAR2 induces upregulation of ICAM-1 in-
dicating a role of this receptor for the regulation of KTC cell
adhesion molecules during cutaneous inflammation.
Several findings in various tissues and cells support the
idea that PAR2 is involved in cell adhesion molecule regu-
lation. For example, PAR2 modulates P-selectin function in a
human endothelial cell line (HMEC-I), stimulates leukocyte
rolling and adherence (Vergnolle, 1999), and upregulates
VCAM-1 cell surface expression on human dermal micro-
vascular endothelial cells (Shpacovitch et al, 2002). Summa-
rized, these in vitro as well as in vivo data clearly indicate a
role of PAR2 for endothelial–leukocyte interactions by regu-
lating cell adhesion molecule expression on endothelial cells.
Further in vivo studies using PAR2-deficient mice indicate
an important role of PAR2 in cutaneous inflammation (Hou
et al, 1998; Steinhoff et al, 1999; Seeliger et al, 2003). In the
mouse contact dermatitis model, our own data show that
ICAM-1 expression is significantly enhanced in wild-type
mice as compared to PAR2-deficient mice both at the RNA
and protein level. Furthermore, application of PAR2 agonists
into human skin leads to upregulation of selectins such as
E-selectin (Seeliger et al, 2003). Together, these results in-
dicate that PAR2 directly regulates cell adhesion molecule
expression in KTC during cutaneous inflammation also
in vivo. Detailed information about the signaling cascades
and molecular mechanisms of PAR2-induced regulation of
cell adhesion molecules is, however, still lacking.
PAR2-induced upregulation of ICAM-1 is mediated by
NF-jB Therefore, we further explored whether PAR2 up-
regulation of ICAM-1 is mediated by NF-kB since it is an
important regulator of ICAM-1 regulation in primary human
KTC. Moreover, the promotor of ICAM-1 shows binding
sites for NF-kB (Hou et al, 1994; Ledebur and Parks, 1995).
By EMSA, we showed that PAR2 agonists concentration-
and time-dependently induce strong NF-kB activation with
a peak after 1 h. Indirect immunofluorescence staining fur-
ther showed translocation of NF-kB to the nucleus upon
PAR2 agonist stimulation (data not shown). Together, PAR2
activates NF-kB in primary human KTC. Moreover, super-
shift assay analysis confirms that the PAR2-induced trans-
located NF-kB complex consists of a p65/p50 heterodimer.
This is in agreement with observations from Kanke et al
(2001) who also observed NF-kB activation in a transfected
human KTC cell line. These authors used PAR2-transfected
NCTC2544 KTC and found that PAR2 agonists stimulated both
JNK and p38 MAP kinases as well as increased NF-kB bind-
ing. It remained, however, still unclear whether PAR2 stimula-
tion also results in NF-kB activation in non-transfected primary
human KTC. Additionally, we determined that activated NF-kB
in primary human KTC consists of a p50/p65 heterodimer. To
confirm the specifity of PAR2-mediated NF-kB activation, we
used various PAR2 agonists including trypsin as well as AP.
To test whether PAR2 may play a role in human skin dis-
eases in which ICAM-1 is upregulated and NF-kB is acti-
vated in human KTC, we examined PAR2 staining in skin
biopsies of patients with AD by immunohistochemistry. Our
studies show that PAR2 immunoreactivity is enhanced in
KTC of lesional AD indicating a role of KTC PAR2 in inflam-
matory human skin diseases.
This observation on the role of PAR2 on ICAM-1 upreg-
ulation in primary human KTC suggests that serine protein-
ases such as tryptase from mast cells, human airway
trypsin-like protease (HAT) (Iwakiri et al, 2004), or other ex-
ogenous or endogenous PAR2 activators, e.g., house dust
mite allergens Der 1, Der p3, and Der p9 (Sun et al, 2001;
Asokhantan et al, 2002) may be capable of influencing ad-
hesion molecule expression on epidermal cells in the skin.
In previous studies, modulation of ICAM-1 expression by
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PAR1 was demonstrated exclusively on endothelial cells
in vitro (Rahman et al, 1999). These studies, however, did
not evaluate the intracellular signaling cascade that may
regulate PAR2-induced regulation of ICAM-1 function.
Moreover, the in vivo relevance of PAR2 protein expression
was not investigated in human skin thus far.
From our observations, we conclude that PAR2 receptor
stimulation on human KTC may serve as an epidermal sen-
sor and is critically involved in inflammatory and immune
responses such as upregulation of cell adhesion molecules,
cytokines (Hou et al, 1998), and growth factors (Wakita et al,
1997) during cutaneous inflammation.
PAR2 may also modulate the function of transient im-
mune cells that interact with KTC during inflammation. This
is supported by findings showing activation of PAR2 in ne-
utrophils (Howells et al, 1997), T cells (Joyce et al, 1997),
eosinophils (Miike et al, 2001), and mast cells (D’Andrea
et al, 2000; Nishikawa et al, 2000) leading to upregulation of
CD 11b (Howells et al, 1997) or release of myeloperoxidase
in neutrophils (Steinhoff et al, 2000), and release of super-
oxide in human eosinophils (Miike et al, 2001). The precise
role of PAR2 on the regulation of transient inflammatory cells
and their interaction with cell adhesion molecules during
cutaneous inflammation is, however, still an enigma and
awaits further investigation.
Our studies demonstrate that PAR2 is enhanced in KTC
of inflammatory skin diseases (AD) and that PAR2 agonists
are capable of directly regulating KTC ICAM-1 expression
by activation. These findings further support a role of PAR2
in the skin during immune response, host defense, and in-
flammation. The PAR2-induced signaling cascades such as
Ca2þ -mobilization (Steinhoff et al, 1999) and NF-kB acti-
vation may contribute to the orchestration of a wide range
of responses during inflammation or tissue repair.
Together, our results indicate that PAR2 plays an impor-
tant role on the regulation of KTC ICAM-1 via NF-kB. This
supports the idea that PAR2 may directly modulate epider-
mal function and KTC–leukocyte interactions by regulating
KTC ICAM-1 expression. This expands our knowledge on
the role of serine proteinases as signaling molecules and
regulators of cutaneous immune responses and inflamma-
tion. Further investigation of the interactions of KTC PAR2
and immune cells and the underlying molecular mecha-
nisms are necessary to fully explore the role of PAR and
serine proteinases that activate PAR2 during cutaneous in-
flammation and cutaneous immune responses.
Materials and Methods
Reagents Trypsin was purchased from Sigma (Deisenhofen, Ger-
many). AP, corresponding to the tethered ligand of PAR2, and RP
were obtained from Dr McMaster (University of Calgary, Canada),
and used as described previously (Steinhoff et al, 2000; Shpacov-
itch et al, 2002). The NF-kB inhibitor BAY11-7082 and MG132
were purchased from Calbiochem (Darmstadt, Germany) or Biomol
(Hamburg, Germany), respectively. Reverse Transcription System
and GeneAmp PCR kit were from Promega (Mannheim, Germany).
TRIzol reagent was purchased from Life Technologies (Karlsruhe,
Germany). [g-32P]ATP was from Hartmann Analytic (Braunschweig,
Germany) and NF-kB-specific oligonucleotide from Promega. TNF-
a was a kind gift of the Knoll AG (Ludwigshafen, Germany).
Supershift antibodies (p50, p52, p65, cRel, and RelB) and the
antibody N19 directed against PAR2 were obtained from Santa
Cruz Biotechnology (Santa Cruz, Heidelberg, Germany). PAR2 B5
was kindly provided by Dr Hollenberg (Calgary, Canada). ICAM-1
antibody was purchased from Immunotech (clone 84H10) (Krefeld,
Germany) and the secondary antidody R-Phycoerythrin-conjugat-
ed goat anti-mouse IgG (Hþ L) from Jackson ImmunoResearch
(West Grove, Pennsylvania). The following primary antibodies were
used: unconjugated monoclonal mouse anti-human CD54 (ICAM-
1) and unconjugated polyclonal rabbit anti-human PAR2 (B5). Sec-
ondary antibodies: R-Phycoerythrin-conjugated affinity-purified
goat anti-mouse were obtained from Dianova (Hamburg, Germa-
ny) and fluorescein isothiocynate (FITC)-conjugated pig anti-rabbit
were obtained from Dako Diagnostika GmbH (Hamburg, Germany).
Cell culture Primary human KTC were purchased from PromoCell
(Heidelberg, Germany). Cells were grown according to manufac-
turer’s instructions in Keratinocyte Basal Medium (Clonetics, San
Diego, California) supplemented with 0.4% bovine pituatary extract
0,1% human epidermal growth factor, 0.1% insulin, 0.1% hydro-
cortisone, 0.1% gentamicin-1000 at 371C in a humidified atmos-
phere containing 5% CO2. Cells in passage 3 were used for
experiments. Trypsin (Life Technologies) was used for detaching
the cells during splitting at passages 1–2. KTC were grown as
described above until 80%–90% confluency and cultured over-
night in medium containing 0.1% gentamicin-1000 only. Cells were
treated with indicated stimuli. The NF-kB inhibitor BAY11-7082
(10 mM) or the proteasome inhibitor MG132 (10 mM) were added to
the cell medium 1 h prior further stimulation. Permission was given
by the Ethical Committee of the University Hospital, Muenster,
Germany.
EMSA KTC (1  105) were plated in 60 mm dishes and allowed to
adhere overnight. After treatment with indicated stimuli cells were
washed with phosphate-buffered saline (PBS) and lysed with total-
cell-extract buffer (20 mM Hepes, pH 7.9, 350 mM NaCl, 1 mM
MgCl2, 0.5 mM EDTA, 0.1 mM EGTA, 20% glycerol, 1% Nonidet P-
40, 1 mM dithiothreitol, 1 mM phenylmethyl-sulfonyl fluoride, and
2 mg per mL each of aprotinin and leupeptin) for 15 min on ice. The
lysate was cleared by centrifugation and stored at 801C. Total cell
extracts containing 10 mg of protein were incubated with the 32P-
labeled NF-kB-specific oligonucleotide. Binding reactions were
performed in a 20 mL volume containing 4 mL of extract, 4 mL of
5  binding buffer (20 mM Hepes, pH 7.5, 50 mM KCl, 1 mM
dithiothreitol, 2.5 mM MgCl2, and 20% Ficoll), 2 mg poly(dI–dC) as
non-specific competitor DNA, 2 mg of bovine serum albumin (BSA),
and 50,000 c.p.m. of the labeled oligonucleotide. After a 15 min
binding reaction at room temperature (RT), samples were loaded
on a 4% non-denaturing polyacrylamide gel. After electrophoresis,
gels were dried and exposed to an X-ray film (Amersham, Freiburg,
Germany). The NF-kB-binding oligonucleotide was end-labeled
using [g-32P]ATP and T4 polynucleotide kinase (Life Technologies),
followed by P-10 gel filtration (Amersham) to remove non-incor-
porated radioactivity. When supershift analysis was performed,
cytosolic extracts were pre-incubated with the antibodies for
30 min on ice.
Immunocytochemistry Immunohistochemistry on tissue sections
was performed as described (Steinhoff et al, 1999; Seeliger et al.
2003). Briefly, 4 mm punch biopsies were taken from lesional skin
(n¼ 8) of patients with AD. Non-lesional skin of AD patients (n¼ 4)
and post-operative material (normal healthy skin from tumor ex-
cisions, n¼ 9) was taken predominantly from the forearm. Patients
did not receive medications or UV-irradiation within 2 wk before
obtaining biopsies. Tissues were snap frozen, embedded in 22-
oxcalcitriol compound (Miles, UK), sectioned, and fixed in 4% PFA
in PBS, pH 7.4 for 20 min. Endogenous peroxidase was quenched
by incubation of slides in a H2O2/methanol solution for 30 min in a
dark chamber. After washing, slides were incubated with primary
antibodies against PAR2 (N19, B5, 1:2000) overnight at 41C in a
PBS buffer containing 5% NGS, 1% BSA, and 0.3% Triton X-100.
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After washing in PBS/0.3% Triton for 3  15 min, incubation using
goat-anti-rabbit-antiserum (1:100) (Dianova, Hamburg, Germany)
followed for 30 min. For the substrate reaction, a diaminobenzidine
(DAB) staining kit (Vector, Heidelberg, Germany) was used with DAB
as a substrate and slides were incubated for 10–15 min at RT in a
dark chamber using H2O2 (0.3%). In controls, primary antibodies
were pre-incubated 24–48 h with the peptides (10–100 mM) used for
immunization or irrelevant species-matched antibody was used to
elucidate background staining. Specimens were examined using a
Zeiss Axioplan microscope (Carl Zeiss AG, Go¨ttingen, Germany).
Semiquantitative RT-PCR Total cellular RNA was extracted from
primary human KTC using the RNA solubility buffer TRIzol as de-
scribed (Steinhoff et al, 1999; Steinhoff et al, 2000). To avoid DNA
contamination, total RNA was treated with 10 U of RQ1Rnase-free
DNase I (Promega) for 30 min at 371C. The amount of total RNA
was measured spectrophotometrically using BioPhotometer (Ep-
pendorf, Hamburg, Germany). RNA (1 mg) was reverse transcribed
to cDNA using Reverse Transcription System and random primers
(Promega, Madison, Wisconsin). Tubes with reaction mixtures were
incubated 10 min at RT, then at 421C for 30 min with 5 min in-
activation of enzyme at 951C, and chilled on ice for 5 min. Samples
were kept at 201C until use.
Nucleotide sequence of PCR primer for human ICAM-1 (prod-
uct size: 446-bp) was generated as previously published (Galdiero
et al, 1997). For PCR amplifications of the housekeeping-gene b-
actin (product size: 832-bp) the following primer pair was used:
forward primer 50-ATC TGG CAC CAC ACC TTC TAC AAT GAG
CTG CG-30 and reverse primer 50-CGT CAT ACT CCT GCT TGC
TGA TCC ACA TCT GC-30.
For PCR amplification the GeneAmp PCR kit (Promega) was used,
taking 1/5 diluted cDNA as template for b-actin undiluted for ICAM-1,
and 1/10 dilution for PAR2. Each PCR product was electrophoresed
through a 1% agarose gel. The PCR product for ICAM-1 or PAR2, and
the housekeeping gene b-actin were amplified from the same com-
plementary DNA. Experiments were performed in triplicates.
Cytoﬂuorometric analysis of human KTC Twenty-four hours after
plating (1  106 cells) stimulated (trypsin, AP, RP) and non-stimulated
KTC were mechanically detached, washed with PBS, and resus-
pended in PBS, 1% BSA. Cells were incubated with the monoclonal
antibodies (MAb) against ICAM-1, respectively, for 60 min at RT.
After centrifugation, cells were washed in PBS, resuspended in
PBS, 1% BSA and 2 mM ethylenediaminetetraacetic acid (EDTA) to
separate the naturally forming clumps. Binding of antibody to the
cells was incubated with R-phycoerythrin-conjugated goat anti-
mouse IgG (Hþ L) (1:100) for 30 min at RT. After extensive washing
with PBS, the reaction was assessed by subsequent flow cyto-
metric analysis with the fluorescence channel 2-histogram profile.
For double-labeling, human KTC were stained and analyzed for
CD54 and PAR2. Cells were washed in PBS (1% fetal calf serum
(FCS)) and subsequently incubated with primary mouse anti-
human monoclonal antibodies (1 mg per mL, CD54) and rabbit
anti-human antibodies (1:200 dilution, PAR2). Therefore, KTC were
additionally washed twice in PBS (1% FCS) after 30 min incubation
on ice and then incubated with PE-conjugated goat anti-mouse
secondary antibody (1 mg per mL) and FITC-conjugated pig anti-
rabbit secondary antibody (1:50 dilution) (no cross-reaction) in PBS
(1% FCS) for additional 30 min on ice. After two more washes with
PBS (1% FCS), cells were finally resuspended in 500 mL PBS
(1% FCS) for analysis. Cells incubated with (PE- and FITC-conju-
gated) secondary antibody alone served as a negative control. Flow
cytometric analyses were performed on a FACScalibur (Becton
Dickinson, Heidelberg, Germany) using CellQuest analysis software.
Results are calculated as percentages above negative control.
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